What is the approximate price of one box of Capmatinib?

Release date: 2026-01-09 14:16:04     Recommended: 149

Capmatinib is indicated for the treatment of metastatic (spread) non-small cell lung cancer (NSCLC) in patients whose tumors harbor abnormal mesenchymal-epithelial transition factor (MET) genes.

What is the approximate price of one box of Capmatinib?

Capmatinib produced by Lucius Pharma is available in a specification of 200mg*60 tablets per bottle, meaning each tablet contains a 200mg dose and there are 60 tablets per bottle.

The price of this medicine may be affected by various factors, mainly including: fluctuations in international exchange rates, cross-border transportation and insurance costs, raw material and production process costs, market supply and demand conditions, as well as differences in tariffs and medical policies across regions. The actual selling price is subject to adjustment.

For current pricing, procurement procedures or medical insurance reimbursement information, it is recommended to contact customer service directly via the QR code on the official website for the most accurate price and relevant consultation.

Precautions Before Use

Before deciding to use any medication, the potential risks of taking the drug must be weighed against its expected benefits. This is a decision that you and your doctor will make together. For this medicine, the following factors should be taken into consideration:

Allergic Reactions

If you have ever had any unusual or allergic reaction to this medicine or any other medicines, please inform your doctor. In addition, if you have a history of any other types of allergies, such as allergies to foods, dyes, preservatives, or animals, please also notify your healthcare professional. For over-the-counter products, carefully read the ingredient list on the label or packaging.

Pediatric Use

Adequate studies to determine the relationship between age and the efficacy of capmatinib in the pediatric population have not been conducted. Safety and effectiveness have not been established.

Geriatric Use

Appropriate studies performed to date have not identified geriatric-specific issues that would limit the use of capmatinib in the elderly.

Lactation

Adequate studies to determine the risk of capmatinib to infants when used by breastfeeding women have not been conducted. Before using this medicine during lactation, the potential benefits should be weighed against the potential risks.

Diseases Affecting Drug Efficacy

The presence of other medical conditions may affect the use of this medicine. Be sure to inform your doctor if you have any other medical problems, especially:

1. Liver disease.

2. Lung or respiratory problems (e.g., interstitial lung disease, pneumonia).